News

Horizon Europe framework programme for research and innovation: Interim evaluation

Published on | 1 month ago

Programmes Horizon Europe

The European Commission has published the interim evaluation of the Horizon Europe Framework Programme for Research and Innovation. It assesses the programme's first results and provides a detailed analysis of its relevance, effectiveness, efficiency, EU added-value and coherence with other EU policies.

The interim evaluation report ('staff working document') can be found at the bottom of this page as well as the 'communication' of the Commission which summarises the findings of the evaluation, highlights the strengths and identifies areas for improvement.

The Commission concluded in the evaluation report, among others, that

  • the programme contributes to the twin transition: climate contribution was 35% of funding by the end of 2023 - digital transformation 8,7%
  • so far, SMEs received grants for a total of € 7,4 billion (17% of the total budget)
  • the programme's internal coherence is hindered by a high number of instruments
  • beneficiaries of lump sum grants are expected to reduce the time spent on reporting by between 96 and 128 person-days per grant over the project lifetime
  • the pilot on blind evaluation confirmes that the blind evaluation of proposals is feasible
  • for each euro the EU has invested in Horizon Europe, it has attracted additional R&I investments of about € 0.24
  • valorisation of R&D outputs remains a challenge
  • it is challenging to draw conclusion of the progress of the missions due to shortcomings of the monitoring framework


In the Communication the Commission states a.o. the following priorities of the coming work programmes/years:

  • to reduce the complexity of the Work Programmes
  • to improve the process of dissemination and uptake of outputs
  • to establish a European centre of expertise on Research Security
  • to decrease the gap in venture capital funding for technology-based start-ups in Europe
  • to focus resources on substantially fewer topics and more open topics
  • to revise several non-financial obligations to produce shorter proposals
  • to fund at least 50% of the budget through lump sum funding by 2027
  • to expand Pillar 3

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1629 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.